Prognostic Factors and 10-Year Survival in Patients with Hepatocellular Carcinoma After Curative Hepatectomy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sung Hoon | - |
dc.contributor.author | Choi, Sae Byeol | - |
dc.contributor.author | Lee, Jae Gil | - |
dc.contributor.author | Kim, Seung Up | - |
dc.contributor.author | Park, Mi-Suk | - |
dc.contributor.author | Kim, Do Young | - |
dc.contributor.author | Choi, Jin Sub | - |
dc.contributor.author | Kim, Kyung Sik | - |
dc.date.accessioned | 2021-09-07T13:46:25Z | - |
dc.date.available | 2021-09-07T13:46:25Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2011-04 | - |
dc.identifier.issn | 1091-255X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/112788 | - |
dc.description.abstract | There were contrary results about the effects of hepatitis B e antigen (HBeAg) positivity on the long-term survival in patients with hepatocellular carcinoma (HCC) after curative resection. Medical records of 170 HCC patients who underwent curative liver resections were retrospectively reviewed. The 10-year survival rate and correlations among clinical, laboratory, and pathological data, especially HBeAg, were analyzed. Fifty-two patients survived more than 10 years. The 10-year actual overall survival (OS) rate was 30.6%, and the actual disease-free survival (DFS) rate was 24.1%. The median OS and DFS were 76 and 35 months, respectively. In multivariate analysis, HBeAg positivity (P = 0.032; hazard ratio [HR], 3.041), presence of a satellite nodule (P = 0.007; HR, 4.166), and elevated ICG R15 (P = 0.003; HR, 4.915) had a significant negative correlation with the 10-year DFS rate. In addition, HBeAg positivity (P = 0.044; HR, 3.725) and recurrence (recur within 1 year, P < 0.001; HR, 41.296; recur after 1 year, P = 0.03; HR, 4.848) were found as independent factors which were negatively correlated to the 10-year OS. The presence of HBeAg was significantly correlated to DFS and OS after curative resection for HCC. Active treatment of B viral hepatitis before and after surgery should be provided to prolong survival in patients with 5-10-cm HCC. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | PERCUTANEOUS ETHANOL INJECTION | - |
dc.subject | LONG-TERM PROGNOSIS | - |
dc.subject | HEPATIC RESECTION | - |
dc.subject | LIVER-TRANSPLANTATION | - |
dc.subject | SURGICAL RESECTION | - |
dc.subject | EARLY RECURRENCE | - |
dc.subject | CLINICOPATHOLOGICAL FEATURES | - |
dc.subject | INTRAHEPATIC RECURRENCE | - |
dc.subject | CONSECUTIVE PATIENTS | - |
dc.subject | NATIONWIDE SURVEY | - |
dc.title | Prognostic Factors and 10-Year Survival in Patients with Hepatocellular Carcinoma After Curative Hepatectomy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Sae Byeol | - |
dc.identifier.doi | 10.1007/s11605-011-1452-7 | - |
dc.identifier.scopusid | 2-s2.0-79953120380 | - |
dc.identifier.wosid | 000288757200008 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROINTESTINAL SURGERY, v.15, no.4, pp.598 - 607 | - |
dc.relation.isPartOf | JOURNAL OF GASTROINTESTINAL SURGERY | - |
dc.citation.title | JOURNAL OF GASTROINTESTINAL SURGERY | - |
dc.citation.volume | 15 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 598 | - |
dc.citation.endPage | 607 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.subject.keywordPlus | PERCUTANEOUS ETHANOL INJECTION | - |
dc.subject.keywordPlus | LONG-TERM PROGNOSIS | - |
dc.subject.keywordPlus | HEPATIC RESECTION | - |
dc.subject.keywordPlus | LIVER-TRANSPLANTATION | - |
dc.subject.keywordPlus | SURGICAL RESECTION | - |
dc.subject.keywordPlus | EARLY RECURRENCE | - |
dc.subject.keywordPlus | CLINICOPATHOLOGICAL FEATURES | - |
dc.subject.keywordPlus | INTRAHEPATIC RECURRENCE | - |
dc.subject.keywordPlus | CONSECUTIVE PATIENTS | - |
dc.subject.keywordPlus | NATIONWIDE SURVEY | - |
dc.subject.keywordAuthor | HBeAg | - |
dc.subject.keywordAuthor | Tumor size | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | 10-Year survival | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.